DXS International secures £409k grant to accelerate development of ExpertCare
( ) , a software company providing clinical decision support solutions, announced it has secured £409,000 of grant funding jointly with Health Innovation East from Innovate UK - the UK's national innovation agency - for further R&D of its AI medicines optimisation prescribing solution, ExpertCare.
The Innovate UK, DXS, and Health Innovation East project has been funded for 18 months, and will consist of two primary elements: First, a cost-to-benefit analysis in the form of a real-world evaluation led by Health Innovation East to assess ExpertCare's utility within a clinical environment. Second, the development and prototyping of 2 additional cardiovascular-related long-term condition AI algorithms for diabetes and hypercholesterolemia.
The Innovate UK grant comes on the back of a 2022 National Institute of Health and Care Research (NIHR) grant award for an initial first stage ExpertCare evaluation, the results of which are soon to be published.
View from Vox
This is a substantial award from Innovate UK that will enable DXS to accelerate its development of ExpertCare, a product promising to revolutionise medicine optimisation. The £409k channeled into intensive R&D, prototyping and testing should fast-track ExpertCare's route to market.
The grant is a key milestone for DXS as it reaffirms industry recognition of ExpertCare as well as the need for digital health solutions to address real problems confronted by the NHS. The grant will bring further exposure to DXS and ExpertCare as Innovate UK is known for driving innovation and growth in the UK's most promising sectors.
DXS's partner on the project, Health Innovation East, is one of 15 UK Academic Health Sciences Networks (AHSNs) that connect NHS and academic organisations, local authorities, charities, and industry. AHSNs as uniquely positioned to identify and spread health innovation at scale.
Today's announcement bringsone step closer to reaching its £4.7m revenue target for FY24, from £3.4m in FY23.
Follow News & Updates from DXS International:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.